---
title: "Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 | WHWK Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288152403.md"
description: "Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 | WHWK Stock News"
datetime: "2026-05-30T10:35:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288152403.md)
  - [en](https://longbridge.com/en/news/288152403.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288152403.md)
---

# Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 | WHWK Stock News

Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 | WHWK Stock News

### Related Stocks

- [WHWK.US](https://longbridge.com/en/quote/WHWK.US.md)

## Related News & Research

- [Whitehawk Therapeutics posts corporate deck highlighting ADC platform and Phase 1 pipeline progress](https://longbridge.com/en/news/295105838.md)
- [Whitehawk Therapeutics Q2 net loss narrows](https://longbridge.com/en/news/295106344.md)
- [Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update | IMNM Stock News](https://longbridge.com/en/news/295573212.md)
- [MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseases](https://longbridge.com/en/news/295105907.md)
- [Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results | CATX Stock News](https://longbridge.com/en/news/295446660.md)